X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Glenmark Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs MYLAN (US) - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   MYLAN
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
MYLAN
Dec-18
GLENMARK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs9303,276-   
Low Rs5171,803-   
Sales per share (Unadj.) Rs322.61,507.4-  
Earnings per share (Unadj.) Rs28.540.9-  
Cash flow per share (Unadj.) Rs39.2323.2-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.01,630.7-  
Shares outstanding (eoy) m282.17514.50-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.21.7 133.2%   
Avg P/E ratio x25.462.0 40.9%  
P/CF ratio (eoy) x18.57.9 235.0%  
Price / Book Value ratio x4.01.6 254.0%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,2061,306,551 15.6%   
No. of employees `00013.735.0 39.2%   
Total wages/salary Rs m18,7180-   
Avg. sales/employee Rs Th6,636.822,158.1 30.0%   
Avg. wages/employee Rs Th1,364.70-   
Avg. net profit/employee Rs Th586.1601.7 97.4%   
INCOME DATA
Net Sales Rs m91,031775,533 11.7%  
Other income Rs m9140-   
Total revenues Rs m91,945775,533 11.9%   
Gross profit Rs m16,154200,679 8.0%  
Depreciation Rs m3,019145,210 2.1%   
Interest Rs m2,85637,300 7.7%   
Profit before tax Rs m11,19318,168 61.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155-2,890 -109.1%   
Profit after tax Rs m8,03921,059 38.2%  
Gross profit margin %17.725.9 68.6%  
Effective tax rate %28.2-15.9 -177.1%   
Net profit margin %8.82.7 325.2%  
BALANCE SHEET DATA
Current assets Rs m69,887433,057 16.1%   
Current liabilities Rs m32,879315,746 10.4%   
Net working cap to sales %40.715.1 268.8%  
Current ratio x2.11.4 155.0%  
Inventory Days Days8184 97.4%  
Debtors Days Days9393 100.2%  
Net fixed assets Rs m28,892150,441 19.2%   
Share capital Rs m282413 68.3%   
"Free" reserves Rs m51,3530-   
Net worth Rs m51,635838,985 6.2%   
Long term debt Rs m41,418905,534 4.6%   
Total assets Rs m125,9542,250,483 5.6%  
Interest coverage x4.91.5 330.8%   
Debt to equity ratio x0.81.1 74.3%  
Sales to assets ratio x0.70.3 209.7%   
Return on assets %8.62.6 333.5%  
Return on equity %15.62.5 620.2%  
Return on capital %15.13.2 474.8%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m26,5980-   
CASH FLOW
From Operations Rs m16,481161,156 10.2%  
From Investments Rs m-10,133-83,300 12.2%  
From Financial Activity Rs m-4,685-75,076 6.2%  
Net Cashflow Rs m1,7701,335 132.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 68.82 Rs / USD

Compare GLENMARK PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: VENUS REMEDIES  PLETHICO PHARMA  LUPIN  SUN PHARMA  DR. DATSONS LABS  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views On News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks (Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock (The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jul 19, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS